Improved Outcomes Using Mesoblast Cells in End-Stage Heart Failure NEW YORK and MELBOURNE, Australia, June 24, 2014 (GLOBE NEWSWIRE) -- Regenerative medicine company Mesoblast Limited (ASX: MSB, USOTC: MBLTY) today announced that trial results evaluating a low dose...